Security Name | Ticker | % of Net Assets |
---|---|---|
ABBVIE INC | ABBV | 6.79% |
AMGEN INC. | AMGN | 4.53% |
GILEAD SCIENCES, INC. | GILD | 4.48% |
VERTEX PHARMACEUTICALS | VRTX | 4.00% |
REGENERON PHARMACEUTICALS | REGN | 3.55% |
CORTEVA INC | CTVA | 3.45% |
ALNYLAM PHARMACEUTICALS | ALNY | 3.18% |
NATERA INC | NTRA | 2.30% |
ASTRAZENECA PLC ADR | AZN | 2.10% |
INSMED INC | INSM | 2.07% |
ROYALTY PHARMA PLC- CL A | RPRX | 2.05% |
BEONE MEDICINES LTD-ADR | BGNE | 2.03% |
BIOGEN IDEC, INC. | BIIB | 1.99% |
ILLUMINA INC | ILMN | 1.90% |
UNITED THERAPEUTICS CORP | UTHR | 1.70% |
NEUROCRINE BIOSCIENCES IN | NBIX | 1.67% |
EXELIXIS, INC. | EXEL | 1.66% |
INCYTE CORP | INCY | 1.56% |
VIATRIS INC | VTRS | 1.52% |
EXACT SCIENCES | EXAS | 1.51% |
BIOMARIN PHARMACEUTICAL | BMRN | 1.51% |
MODERNA INC | MRNA | 1.49% |
JAZZ PHARMACEUTICALS PLC | JAZZ | 1.39% |
BLUEPRINT MEDICI | BPMC | 1.37% |
BRIDGEBIO PHARMA INC | BBIO | 1.33% |
CRISPR THERAPEUTICS AG | CRSP | 1.28% |
ARGENX SE - ADR | ARGX | 1.24% |
IONIS PHARMACEUTICALS, IN | IONS | 1.24% |
GUARDANT HEALTH INC | GH | 1.23% |
HALOZYME THERAPEUTICS INC | HALO | 1.18% |
BIONTECH SE-ADR | BNTX | 1.17% |
LEGEND BIOTECH CORP-ADR | LEGN | 1.15% |
REVOLUTION MEDICINES INC | RVMD | 1.14% |
ALKERMES PLC | ALKS | 1.10% |
MEDPACE HOLDINGS | MEDP | 1.07% |
TG THERAPEUTICS | TGTX | 1.06% |
ROIVANT SCIENCES LTD | ROIV | 1.01% |
AKERO THERAPEUTICS INC | AKRO | 0.95% |
VAXCYTE INC | PCVX | 0.93% |
CYTOKINETICS INC | CYTK | 0.92% |
PTC THERAPEUTICS | PTCT | 0.92% |
ADMA BIOLOGICS INC | ADMA | 0.91% |
SPRINGWORKS THERAPEUTICS | SWTX | 0.89% |
PROTAGONIST THER | PTGX | 0.87% |
AVIDITY BIOSCIENCES INC | RNA | 0.81% |
AXSOME THERAPEUT | AXSM | 0.79% |
ULTRAGENYX PHARM | RARE | 0.79% |
ACADIA PHARMACEUTICALS IN | ACAD | 0.78% |
VIKING THERAPEUTICS INC | VKTX | 0.77% |
TWIST BIOSCIENCE CORP | TWST | 0.73% |
VERACYTE INC | VCYT | 0.71% |
KRYSTAL BIOTECH INC | KRYS | 0.67% |
NUVALENT INC-A | NUVL | 0.66% |
RECURSION PHARMACEUTICALS | RXRX | 0.65% |
ARROWHEAD PHARMACEUTICALS | ARWR | 0.65% |
CRINETICS PHARMACEUTICALS | CRNX | 0.64% |
AGIOS PHARMACEUT | AGIO | 0.63% |
SUMMIT THERAPEUTICS INC | SMMT | 0.63% |
APELLIS PHARMACE | APLS | 0.63% |
IDEAYA BIOSCIENCES INC | IDYA | 0.61% |
AMICUS THERAPEUTICS INC | FOLD | 0.61% |
BEAM THERAPEUTICS INC | BEAM | 0.60% |
ASCENDIS PHA-ADR | ASND | 0.58% |
DENALI THERAPEUT | DNLI | 0.58% |
CELLDEX THERAPEUTICS INC | CLDX | 0.56% |
ARCELLX INC | ACLX | 0.56% |
MADRIGAL PHARMAC | MDGL | 0.56% |
IMMUNOVANT INC | IMVT | 0.50% |
DYNAVAX TECHNOLOGY | DVAX | 0.50% |
INTELLIA THERAPE | NTLA | 0.49% |
NOVAVAX INC | NVAX | 0.44% |
SAREPTA THERAPEU | SRPT | 0.41% |
DYNE THERAPEUTICS INC | DYN | 0.38% |
GERON CORP | GERN | 0.21% |
IOVANCE BIOTHERAPEUTICS | IOVA | 0.20% |
Other (Cash, derivatives and other liabilities) | 0.28% | |
Total: |
Read a prospectus and summary prospectus (if available) carefully before investing. It contains the investment objective, risks charges, expenses and the other information, which should be considered carefully before investing. To obtain a prospectus and summary prospectus (if available) click here or call 800.820.0888.
Investing involves risk, including the possible loss of principal.
Guggenheim Investments represents the following affiliated investment management businesses of Guggenheim Partners, LLC: Guggenheim Partners Investment Management, LLC, Security Investors, LLC, Guggenheim Funds Distributors, LLC, Guggenheim Funds Investment Advisors, LLC, Guggenheim Corporate Funding, LLC, Guggenheim Wealth Solutions, LLC, Guggenheim Partners Europe Limited, Guggenheim Partners Japan Limited, GS GAMMA Advisors, LLC, and Guggenheim Private Investments, LLC.
© 2025 Guggenheim Investments. All Rights Reserved.
Research our firm with FINRA Broker Check.
• Not FDIC Insured • No Bank Guarantee • May Lose Value
This website is directed to and intended for use by citizens or residents of the United States of America only. The material provided on this website is not intended as a recommendation or as investment advice of any kind, including in connection with rollovers, transfers, and distributions. Such material is not provided in a fiduciary capacity, may not be relied upon for or in connection with the making of investment decisions, and does not constitute a solicitation of an offer to buy or sell securities. All content has been provided for informational or educational purposes only and is not intended to be and should not be construed as legal or tax advice and/or a legal opinion. Always consult a financial, tax and/or legal professional regarding your specific situation. Investing involves risk, including the possible loss of principal.